Search

Displaying results 3091 - 3100 of 3864 in total
  1. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).

  2. Drug

    Rocaglamide

    go.drugbank.com/drugs/DB15495
    Experimental

    [A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_. … [A186760] Rocaglamides are secondary metabolites of the plant genus _Aglaia_, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties

  3. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 is an antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis (MS). It is considered a sm...

  4. Drug

    KB3305

    go.drugbank.com/drugs/DB06349
    Experimental

    KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.

    Synonyms: (4R)-4-((3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-DIHYDROXY-3-(2-(4-((8S,11R,13S,14S,17S)-17-HYDROXY-13-METHYL-3-OXO-17-PROP-1-YNYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA(A)PHENANTHREN-11-YL)-N-METHYL-ANILINO
  5. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28]. … D2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic

  6. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Folika-NC
  7. Drug

    Stem-cell derived exosome vesicle products

    go.drugbank.com/drugs/DB15743
    Experimental

    These products originate from multiple cellular types, including immunocytes, tumor cells, and mesenchymal stem cells (MSCs) originating from various tissues. … Exosomes from MSCs carry cytokines and growth factors, like TGFB1, IL-6, IL-10, and hepatocyte growth factor (HGF); all are shown to be immunomodulatory.

  8. Drug

    Choline salicylate

    go.drugbank.com/drugs/DB14006
    ApprovedNutraceutical

    Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers [L2134].

  9. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.

  10. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.